Dose intensive chemotherapy in small cell lung cancer

Lung Cancer

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Wolf, Martin ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Dose intensified treatment; High dose chemotherapy; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; LUNG SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 0034828862     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00313-0     Document Type: Article

References (31)

1. A randomised comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: a phase III trial of the Southeastern Cancer study group
2. Cotrimoxazol prophylaxis during high dose chemotherapy of small cell lung Cancer
3. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin with cyclophosphamide plus vincristine and with high dose cyclophosphamide plus vincristine in the treatment of small cell carcinoma of the lung: a randomised trial of the Bristol Lung Cancer study group
4. Prospective randomised comparison of high dose and standard dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer
5. Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses
6. Initial chemotherapeutic doses and survival in patients in patients with limited small cell lung cancer
7. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: a Cancer Research Campaign trial
8. Multiple drug weekly chemotherapy versus combination regimen in small cell lung cancer: a phase III randomised study conducted by the European Lung Cancer Working Party
9. Intensive weekly chemotherapy for the treatment of extensive stage small cell lung cancer
10. A randomised study of CODE versus alternating CAV/PE for extensive stage small cell lung cancer: an intergroup study of the National Cancer Institute if Canada Clinical Trials Group and the Southwest Oncology Group
11. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive disease small cell lung cancer. The Japanese Clinical Oncology Group
12. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cel lung cancer
13. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer
14. Recombinant granolucyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
15. Dose ranging study of recombinant human granulocyte-macrophage colony stimulating factor in small cell lung carcinoma
16. Chemoradiotherapy with or without granulocyte-macrophage colony stimulating factor in the treatment of limited stage small cell lung cancer: A prospective Phase III randomised trial of the Southwest Oncology group
17. Experience with GM-CSF in the treatment of solid tumors
18. Effect of granulocyte-macrophage colony stimulating factor and dose intensification of V-Ice Chemotherapy in small cell lung cancer: a prospective randomized study of 300 patients
19. Improving Survival without Reducing Quality of Life in Small Cell Lung Cancer Patients by Increasing the dose Intensity of Chemotherapy with Granulocyte Colony Stimulating Factor Support: Results of a British Medical Research Council Multicenter Randomized Trial
20. Can cytotoxic dose-intensity be increased by using granulcyte colony stimulating factor? A randomised controlled trial of lenograstim in small cell lung cancer
21. Treatment intensification with GM-CSF in patients with non-metastatic small cell lung cancer (NMSCLC). Results of a mutlicenter trial including 330 patients
22. Use of hematopoietic progenitors in Whole blood to support dose dense chemotherapy: A randomized Phase II trial in small cell lung cancer
23. High dose intensification therapie with autologous bone marow support for limited small cell bronchogenic carcinoma
24. Treatment of limited small cell lung cancer with concurrent etoposide/cisplatin and radiotherapy foolowed by intensification with high dose cyclophosphamide: A Southwest Oncology Group Study
25. Standard versus dose intensified chemotherapy with sequential reinfusion of peripheral blood cells in SCLC
26. Dose-Intensive Therapy for Limited-Stage Small Cell Lung Cancer: Long-Term Outcome
27. Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomised study
28. Dose intensive therapy with etoposide, ifosfamide, cisplatin and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive disease small cell lung cancer
29. Multiple Courses of High-Dose Ifosfamide, Carboplatin and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small Celll Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation
30. Tandem High Dose Chemotherapy (THD) in Patients (Pts) with Small Cell Lung Cancer (SCLC)